专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明授权

US07939505B2 Amino acid lipids and uses thereof 有权
公开(公告)号：US07939505B2
公开(公告)日：2011-05-10
申请号：US12114284
申请日：2008-05-02
申请人： Steven C. Quay , Michael Houston, Jr. , Pierrot Harvie , Roger C. Adami , Renata Fam , Mary Gallagher Prieve , Kathy Lynn Fosnaugh , Shaguna Seth
发明人： Steven C. Quay , Michael Houston, Jr. , Pierrot Harvie , Roger C. Adami , Renata Fam , Mary Gallagher Prieve , Kathy Lynn Fosnaugh , Shaguna Seth
IPC分类号： A61K47/14 , A61K47/18 , A61K48/00 , C07C279/14
CPC分类号： A61K47/183 , A61K9/127 , A61K9/1271 , A61K9/1272 , A61K31/7088 , A61K47/18 , A61K47/22 , A61K47/28 , A61K47/44 , A61K48/0025 , A61K48/0033 , C07C235/02 , C07C279/12 , C07C279/14 , C07D213/40 , C07D213/56 , C07D233/26 , C07D233/64 , C12N15/111 , C12N15/113 , C12N15/1131 , C12N15/1138 , C12N15/88 , C12N2310/14 , C12N2320/32 , Y10S514/943
摘要： This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.

72. 发明申请

US20110033531A1 Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof 审中-公开
标题翻译：第二代脂肪酸组合物，制剂及其使用和合成方法
公开(公告)号：US20110033531A1
公开(公告)日：2011-02-10
申请号：US12852620
申请日：2010-08-09
申请人： Steven C. Quay
发明人： Steven C. Quay
IPC分类号： A61K9/48 , A61K31/355 , A61P9/00 , A61P9/10 , A61P9/12 , A61P3/06
CPC分类号： A61K31/202 , A23L33/12 , A61K9/0053 , A61K9/145 , A61K9/146 , A61K9/4858 , A61K9/4866 , A61K31/16 , A61K31/164 , A61K31/353 , A61K31/355
摘要： An orally administered fatty acid composition for the treatment of cardiovascular diseases, and a method of treating same, are provided. The compound includes 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol. The EPA ethanolamide and the DHA ethanolamide are preferably each substantially in a range of 100-900 mg per dosage form. The at least one tocotrienol is substantially in a range of 10-500 mg per dosage form. The at least one tocotrienol includes at least one of α-tocotrienol, β-tocotrienol, γ-tocotrienol, or δ-tocotrienol and is preferably substantially tocopherol-free. The composition may take the form of a medical food or a pharmaceutical preparation. A preferred formulation of the composition includes approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg δ-tocotrienol. The EPA and DHA ethanolamides may be synthesized from fatty acid triglycerides.
摘要翻译：提供了用于治疗心血管疾病的口服给药脂肪酸组合物及其治疗方法。该化合物包括5Z，8Z，11Z，14Z，17Z-二十碳五烯酸乙醇酰胺（EPA乙醇酰胺），4Z，7Z，10Z，13Z，16Z，19Z-二十二碳六烯酸乙醇酰胺（DHA乙醇酰胺）和至少一种生育三烯酚。 EPA乙醇酰胺和DHA乙醇酰胺优选地每个剂型基本上在100-900mg的范围内。至少一种生育三烯酚基本上在每种剂型10-500mg的范围内。至少一种生育三烯酚包括α-生育三烯酚，生育三烯酚，γ-生育三烯酚或δ-生育三烯酚中的至少一种，优选基本上不含生育酚。组合物可以采取医疗食品或药物制剂的形式。组合物的优选制剂包括约525mg EPA乙醇酰胺，约315mg DHA乙醇酰胺和约50mgδ-生育三烯酚。 EPA和DHA乙醇酰胺可以由脂肪酸甘油三酯合成。

73. 发明授权

US07879349B2 Cyanocobalamin low viscosity aqueous formulations for intranasal delivery 有权
标题翻译：用于鼻内给药的氰钴胺素低粘度含水制剂
公开(公告)号：US07879349B2
公开(公告)日：2011-02-01
申请号：US12079875
申请日：2008-03-27
申请人： Steven C. Quay , Peter C. Aprile , Zenaida O. Go , Anthony P. Sileno
发明人： Steven C. Quay , Peter C. Aprile , Zenaida O. Go , Anthony P. Sileno
IPC分类号： A61F13/00 , C07H23/00 , A61K31/70
CPC分类号： A61K9/0043 , A61K9/08 , A61K31/7056 , A61K31/714 , A61K47/10 , A61K47/12 , A61K47/186
摘要： A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.
摘要翻译：一种由氰钴胺素和水组成的稳定的药用无汞水溶液，其中所述氰钴胺溶液适合于鼻内给药，其粘度小于约1000cPs，其中所述氰钴胺溶液在鼻内给药时具有氰钴胺素的生物利用度相对于肌内注射氰钴胺素至少约7％，条件是溶液基本上不含汞和含汞化合物。本发明还涉及提高脑脊髓液（CSF）中维生素B12水平的方法，其包括向鼻内施用足够量的无汞氰钴胺溶液，以增加CSF中维生素B12的平均比例在血清（B12 CSF / B12血清×100）中至少约1.1，其包括鼻内施用氰钴胺水溶液，其中所述氰钴胺溶液相对于肌内注射氰钴胺素具有至少7％的生物利用度。

74. 发明申请

US20100112687A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES THEREOF 审中-公开
标题翻译：用于抑制ERBB家族基因表达的核酸化合物及其用途
公开(公告)号：US20100112687A1
公开(公告)日：2010-05-06
申请号：US12528619
申请日：2008-02-28
申请人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
发明人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
IPC分类号： C12N5/071 , C07H21/02
CPC分类号： C12N15/1138 , C12N2310/14 , C12N2310/321 , C12N2310/3231 , C12N2310/3521
摘要： The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing one or more ERBB family gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to one or more ERBB family mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine and optionally other modifications or combinations thereof. Also provided are methods of decreasing expression of one or more ERBB family gene in a cell or in a subject to treat one or more ERBB family-related disease.
摘要翻译：本公开提供能够降低或沉默一种或多种ERBB家族基因表达的meroduplex核糖核酸分子（mdRNA）。本公开的mdRNA包含至少三条链，其结合形成由切口或间隙分开的至少两个不重叠的双链区域，其中一条链与一个或多个ERBB家族mRNA互补。此外，meroduplex可以具有至少一个被5-甲基尿苷取代的尿苷和任选的其它修饰或组合。还提供了降低细胞或受试者中一种或多种ERBB家族基因表达以治疗一种或多种ERBB家族相关疾病的方法。

75. 发明申请

US20100055784A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING WNT GENE EXPRESSION AND USES THEREOF 审中-公开
标题翻译：用于抑制WNT基因表达的核酸化合物及其用途
公开(公告)号：US20100055784A1
公开(公告)日：2010-03-04
申请号：US12529532
申请日：2008-03-03
申请人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
发明人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
IPC分类号： C12N5/071 , C07H21/02
CPC分类号： C12N15/1135 , C12N2310/14
摘要： The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing WNT1, WNT2, or WNT3A gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a WNT1, WNT2, or WNT3A mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a WNT1, WNT2, or WNT3A gene in a cell or in a subject to treat a WNT1, WNT2, or WNT3A-related disease.
摘要翻译：本公开提供能够降低或沉默WNT1，WNT2或WNT3A基因表达的meroduplex核糖核酸分子（mdRNA）。本公开的mdRNA包含至少三条链，其组合形成由切口或间隙隔开的至少两个非重叠双链区域，其中一条链与WNT1，WNT2或WNT3A mRNA互补。此外，meroduplex可以具有至少一个尿苷是5-甲基尿苷，核苷是锁定的核酸或任选的其它修饰，以及它们的任何组合。还提供减少细胞或受试者中WNT1，WNT2或WNT3A基因表达以治疗WNT1，WNT2或WNT3A相关疾病的方法。

76. 发明申请

US20100047909A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF FAMILY GENE EXPRESSION AND USES THEREOF 审中-公开
标题翻译：用于抑制VEGF家族基因表达的核酸化合物及其用途
公开(公告)号：US20100047909A1
公开(公告)日：2010-02-25
申请号：US12528508
申请日：2008-02-28
申请人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
发明人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
IPC分类号： C12N5/02 , C07H21/02
CPC分类号： C12N15/1136 , C12N15/1131 , C12N2310/14 , C12N2310/3231 , C12N2310/533
摘要： The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing one or more VEGF family gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to one or more VEGF family mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine and optionally other modifications or combinations thereof. Also provided are methods of decreasing expression of one or more VEGF family gene in a cell or in a subject to treat one or more VEGF family-related disease.
摘要翻译：本公开提供能够降低或沉默一种或多种VEGF家族基因表达的meroduplex核糖核酸分子（mdRNA）。本公开的mdRNA包含至少三条链，其结合形成由切口或间隙隔开的至少两个非重叠双链区域，其中一条链与一个或多个VEGF家族mRNA互补。此外，meroduplex可以具有至少一个被5-甲基尿苷取代的尿苷和任选的其它修饰或组合。还提供减少细胞或受试者中一种或多种VEGF家族基因表达以治疗一种或多种VEGF家族相关疾病的方法。

77. 发明申请

US20080287383A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB GENE EXPRESSION AND USES THEREOF 审中-公开
标题翻译：用于抑制ERBB基因表达的核酸化合物及其用途
公开(公告)号：US20080287383A1
公开(公告)日：2008-11-20
申请号：US12039658
申请日：2008-02-28
申请人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
发明人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
IPC分类号： A61K31/7105 , C07H21/02 , A61P35/00
CPC分类号： C12N15/1135 , C12N15/1137 , C12N15/1138 , C12N2310/14
摘要： The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing ERBB gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an ERBB mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of an ERBB gene in a cell or in a subject to treat an ERBB-related disease.
摘要翻译：本公开提供能够降低或沉默ERBB基因表达的meroduplex核糖核酸分子（mdRNA）。本公开的mdRNA包含至少三条链，其结合形成由切口或间隙分开的至少两个不重叠的双链区域，其中一条链与ERBB mRNA互补。此外，meroduplex可以具有至少一个用5-甲基尿苷取代的尿苷，被锁定的核酸替代的核苷，或任选的其它修饰，以及它们的任何组合。还提供减少细胞或受试者中ERBB基因表达以治疗ERBB相关疾病的方法。

78. 发明申请

US20070254362A1 COMPOSITIONS AND METHODS EMPLOYING UNIVERSAL-BINDING NUCLEOTIDES FOR TARGETING MULTIPLE GENE VARIANTS WITH A SINGLE siRNA DUPLEX 审中-公开
标题翻译：组合物和方法采用通用结合核酸，用单克隆双链体靶向多种基因变异体
公开(公告)号：US20070254362A1
公开(公告)日：2007-11-01
申请号：US11610403
申请日：2006-12-13
申请人： Steven C. Quay , James Anthony McSwiggen
发明人： Steven C. Quay , James Anthony McSwiggen
IPC分类号： C12N5/06 , C07H21/02
CPC分类号： C12N15/111 , C12N15/113 , C12N2310/14 , C12N2310/321 , C12N2310/33 , C12N2310/331 , C12N2320/50 , C12N2320/51 , C12N2310/3521
摘要： Provided are siRNA molecules of between about 15 base-pairs and about 40 base-pairs comprising one or more universal-binding nucleotide such as inosine, 1-β-D-ribofuranosyl-5-nitroindole, and 1-β-D-ribofuranosyl-3-nitropyrrole, compositions comprising one or more universal-binding nucleotide comprising siRNA, and methods for making and for using such universal-binding nucleotide comprising siRNA molecules to increase the specific binding of the modified siRNA molecule to variants of a target sequence such as, for example, when in contact with a biological sample and to reduce off-target effects of the siRNA molecule.
摘要翻译：提供包含一个或多个通用结合核苷酸如肌苷，1-β-D-呋喃核糖-5-硝基吲哚和1-β-D-呋喃核糖基-5-硝基吲哚之间的约15个碱基对和约40个碱基对的siRNA分子。 3-硝基吡咯，包含一种或多种包含siRNA的通用结合核苷酸的组合物，以及用于制备和使用包含siRNA分子的通用结合核苷酸的方法，以增加修饰的siRNA分子与靶序列变体的特异性结合，例如当与生物样品接触并且减少siRNA分子的脱靶效应时。

79. 发明授权

US07229966B2 Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity 失效
公开(公告)号：US07229966B2
公开(公告)日：2007-06-12
申请号：US10780325
申请日：2004-02-17
申请人： Steven C. Quay , Gordon Brandt , Mary S. Kleppe , Conor J. MacEvilly
发明人： Steven C. Quay , Gordon Brandt , Mary S. Kleppe , Conor J. MacEvilly
IPC分类号： A61K38/17 , A61K38/28 , C07K14/435 , B05B11/02
CPC分类号： A61K9/0043 , A61K31/045 , A61K31/70 , A61K31/7012 , A61K31/715 , A61K31/724 , A61K38/22
摘要： Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.

80. 发明授权

US06887210B2 Devices and methods for obtaining mammary fluid samples for evaluating breast diseases, including cancer 失效
标题翻译：用于获得用于评估乳腺疾病（包括癌症）的乳液样品的装置和方法
公开(公告)号：US06887210B2
公开(公告)日：2005-05-03
申请号：US10002540
申请日：2001-11-13
申请人： Steven C. Quay
发明人： Steven C. Quay
IPC分类号： G01N33/48 , A61B5/00 , A61B10/00 , A61B10/02 , A61M1/06 , C12Q1/04 , B65D81/00
CPC分类号： C12Q1/6886 , A61B5/14546 , A61B10/0041 , A61B10/0045 , A61B10/0096 , A61M1/06 , A61M1/064 , A61M1/066 , A61M2205/075
摘要： Biological samples of mammary fluid or components thereof are obtained using a breast pump device coupled with a solid phase sample collection medium, alternatively facilitated by administering oxytocin to the subject. The breast pump device stimulates expression of mammary fluid and provides for collection of diagnostic samples to evaluate breast disease, including cancer. The biological sample may include whole cells or cellular components, purified or bulk proteins, glycoproteins, peptides, nucleotides or other desired constituents comprising a breast disease marker. Methods, kits and adapter devices relating to the breast pump device are also provided. Yet additional methods, devices, accessories, and materials are provided for laboratory handling and processing of breast fluid samples and for related diagnostic methods.
摘要翻译：使用与固相样品收集介质偶联的吸乳器装置获得乳液或其组分的生物样品，或者通过向受试者施用催产素来辅助。乳房泵装置刺激乳腺液的表达，并提供收集诊断样品以评估乳腺疾病，包括癌症。生物样品可以包括全细胞或细胞组分，纯化或体蛋白，糖蛋白，肽，核苷酸或包含乳腺疾病标记的其它所需组分。还提供了与吸奶器装置相关的方法，套件和适配器装置。还提供了其他方法，设备，附件和材料，用于乳液样品的实验室处理和加工以及相关的诊断方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式